EPM-01

About Epirium Bio

Epirium Bio is a private, clinical-stage biotech founded in 2008, focused on a novel platform targeting mitochondrial biogenesis and function via PGE-2 signaling. The company's most advanced asset, MF-300, is in Phase 2b for sarcopenia, with earlier-stage programs exploring indications like Becker muscular dystrophy, spinal muscular atrophy, and idiopathic pulmonary fibrosis. Led by CEO Russell J. Cox and backed by an $85M Series A, Epirium is advancing its pipeline of oral therapies for diseases with significant unmet need.

Therapeutic Areas